These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32159944)

  • 21. Quantitative characterization of protein nanostructures using atomic force microscopy.
    Segers-Nolten I; van der Werf K; van Raaij M; Subramaniam V
    Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():6609-12. PubMed ID: 18003540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S100A9 Alters the Pathway of Alpha-Synuclein Amyloid Aggregation.
    Toleikis Z; Ziaunys M; Baranauskiene L; Petrauskas V; Jaudzems K; Smirnovas V
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson's disease.
    de Oliveira GAP; Silva JL
    Commun Biol; 2019; 2():374. PubMed ID: 31633065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baicalein exhibits differential effects and mechanisms towards disruption of α-synuclein fibrils with different polymorphs.
    Yao Y; Tang Y; Zhou Y; Yang Z; Wei G
    Int J Biol Macromol; 2022 Nov; 220():316-325. PubMed ID: 35981677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (De)stabilization of Alpha-Synuclein Fibrillary Aggregation by Charged and Uncharged Surfactants.
    Loureiro JA; Andrade S; Goderis L; Gomez-Gutierrez R; Soto C; Morales R; Pereira MC
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
    Rutherford NJ; Moore BD; Golde TE; Giasson BI
    J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein.
    Ohgita T; Namba N; Kono H; Shimanouchi T; Saito H
    Sci Rep; 2022 Apr; 12(1):6770. PubMed ID: 35474118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sensitive assay reveals structural requirements for α-synuclein fibril growth.
    Dhavale DD; Tsai C; Bagchi DP; Engel LA; Sarezky J; Kotzbauer PT
    J Biol Chem; 2017 Jun; 292(22):9034-9050. PubMed ID: 28373279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The α-synuclein hereditary mutation E46K unlocks a more stable, pathogenic fibril structure.
    Boyer DR; Li B; Sun C; Fan W; Zhou K; Hughes MP; Sawaya MR; Jiang L; Eisenberg DS
    Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3592-3602. PubMed ID: 32015135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Mutations and Post-Translational Modifications on α-Synuclein In Vitro Aggregation.
    Pancoe SX; Wang YJ; Shimogawa M; Perez RM; Giannakoulias S; Petersson EJ
    J Mol Biol; 2022 Dec; 434(23):167859. PubMed ID: 36270580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Synuclein aggregation at low concentrations.
    Afitska K; Fucikova A; Shvadchak VV; Yushchenko DA
    Biochim Biophys Acta Proteins Proteom; 2019; 1867(7-8):701-709. PubMed ID: 31096048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties.
    Ulrih NP; Barry CH; Fink AL
    Biochim Biophys Acta; 2008 Oct; 1782(10):581-5. PubMed ID: 18692132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α-synuclein aggregation and membrane binding.
    Ghosh D; Sahay S; Ranjan P; Salot S; Mohite GM; Singh PK; Dwivedi S; Carvalho E; Banerjee R; Kumar A; Maji SK
    Biochemistry; 2014 Oct; 53(41):6419-21. PubMed ID: 25268550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
    Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
    J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphism of Alpha-Synuclein Amyloid Fibrils Depends on Ionic Strength and Protein Concentration.
    Ziaunys M; Sakalauskas A; Mikalauskaite K; Smirnovas V
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.